1-(溴甲基)-3,5-二乙氧基苯 | 238405-74-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(溴甲基)-3,5-二乙氧基苯
• 英文名称: 1-(bromomethyl)-3,5-diethoxybenzene
• 英文别名: 3,5-diethoxylbenzyl bromide；diethyl 5-(bromomethyl)benzene-1,3-dioate；3,5-diethoxybenzyl bromide
• CAS: 238405-74-8
• 化学式: C₁₁H₁₅BrO₂
• 分子量: 259.143
• InChiKey: HSTNPLPOTDVPQS-UHFFFAOYSA-N

物化性质

• 沸点：
  322.5±27.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(溴甲基)-3,5-二乙氧基苯 在 chromium(VI) oxide 、 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 N-溴代丁二酰亚胺(NBS) 、 potassium tert-butylate 、 氨 、 水 、 lithium 、 对甲苯磺酸 、 溶剂黄146 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 溶剂黄146 、 甲苯 为溶剂， 反应 63.5h， 生成 dysidavarone A
  参考文献：
  名称：

  dysidavarone A的全合成

  摘要：

  dysidavarone A是从南海海绵Dysidea avara分离得到的倍半萜烯，据报道它显示出显着的抗癌活性。由于该化合物具有独特的“ dysidavarane”碳骨架和强大的生物活性，因此开发了7个步骤的dysidavarone A立体选择性合成。合成的关键步骤涉及立体选择性还原烷基化，分子内α-芳基化和双键迁移反应。还评估了dysidavarone A对人肾癌细胞系786-O和人前列腺癌细胞系PC-3的抗增殖活性。

  DOI：

  10.1016/j.tet.2016.05.073
• 作为产物：
  描述：

  3,5-二羟基苯甲醇 在 18-冠醚-6 、 三溴化磷 、 potassium carbonate 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 50.5h， 生成 1-(溴甲基)-3,5-二乙氧基苯
  参考文献：
  名称：

  构象效应对哑铃形客体进入 Oxatub[4] 芳烃腔的动力学

  摘要：

  通过宿主的三个构象异构体的参与，在一个包含紫罗碱基客体和氧杂蒽酮 [4] 芳烃的双组分系统中观察到复杂的动力学行为。此外，一种前所未有的涉及客体倾斜构造的穿线机制被揭示为非常快速的动力学和具有非常大的塞子的客体穿线的原因。

  DOI：

  10.1002/anie.202212305

文献信息

• PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN
  申请人：Breitenstein Werner

  公开号：US20100087427A1

  公开（公告）日：2010-04-08

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.

  小说3-单一、3,4-二和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素不适当活性的疾病（=失调）；该类化合物用于制备用于治疗依赖于肾素不适当活性的疾病的制药配方；该类化合物用于治疗依赖于肾素不适当活性的疾病；包括所述取代吡咯烷化合物的制药配方和/或包括给予所述取代吡咯烷化合物的治疗方法，以及描述了制备所述取代吡咯烷化合物的新型中间体和部分步骤。所述取代吡咯烷化合物特别是公式I的取代基如说明书所述。
• Catalytic Asymmetric Inverse‐Electron‐Demand Diels–Alder Reactions of 2‐Pyrones with Indenes: Total Syntheses of Cephanolides A and B
  作者：Yang Lu、Meng‐Meng Xu、Zhi‐Mao Zhang、Junliang Zhang、Quan Cai

  DOI：10.1002/anie.202112223

  日期：2021.12.13

  Catalytic asymmetric all-carbon-based inverse-electron-demand Diels–Alder reactions of 2-pyrones with electronically unbiased indenes have been realized. This method enables the rapid and enantioselective construction of a wide range of hexahydrofluorenyl bridged-lactone scaffolds. Based on this method, asymmetric total syntheses of cephanolides A and B have been accomplished.

  2-吡喃酮与电子无偏茚的催化不对称全碳基逆电子需求 Diels-Alder 反应已经实现。这种方法能够快速和对映选择性地构建范围广泛的六氢芴基桥接内酯支架。基于该方法，完成了头孢内酯A和B的不对称全合成。
• WO2006/55434
  申请人：——

  公开号：——

  公开（公告）日：——
• Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors
  作者：Robert J. Cherney、James J.-W. Duan、Matthew E. Voss、Lihua Chen、Li Wang、Dayton T. Meyer、Zelda R. Wasserman、Karl D. Hardman、Rui-Qin Liu、Maryanne B. Covington、Mingxin Qian、Sandhya Mandlekar、David D. Christ、James M. Trzaskos、Robert C. Newton、Ronald L. Magolda、Ruth R. Wexler、Carl P. Decicco

  DOI：10.1021/jm020475w

  日期：2003.5.1

  Elevated levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with several inflammatory diseases, and therefore, strategies for its suppression have become important targets in drug discovery. Our efforts to suppress TNF-alpha have centered on the inhibition of TNF-alpha converting enzyme (TACE) through the use of hydroxamate inhibitors. Starting from broad-spectrum matrix metalloproteinase (MMP) inhibitors, we have designed and synthesized novel benzothiadiazepines as potent and selective TACE inhibitors. The benzothiadiazepines were synthesized with variation in P1 and P1' in order to effect potency and selectivity. The inhibitors were evaluated versus porcine TACE (pTACE), and the initial selectivity was assessed with counterscreens of MMP-1, -2, and -9. Several potent and selective inhibitors were discovered with compound 41 being the most active against pTACE (K-i = 5 nM) while still maintaining good selectivity versus the MMP's (at least 75-fold). Most compounds were assessed in the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA) to determine their ability to suppress TNF-alpha. Compound 32 was the most potent compound in the PBMC assay (IC50 = 0.35 muM), while compound 62 was the most active in the WBA (IC50 = 1.4 muM).
• NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP1054877A1

  公开（公告）日：2000-11-29